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REVIEWS
BREAST AUGMENTATION AND BREAST IMPLANTS 
EVOLUTION
Yordan Yordanov 
Unit of Plastic Surgery and Burns, Military Medical Academy of Sofia
ABSTRACT
The female breast is a universal symbol of sexuality, motherhood and femininity today, dating back even 
to the time of ancient cave paintings. Historically, women have long sought breast enlargement to improve 
physical proportions, to foster a more feminine appearance, or to enhance self-image. When compared to 
the aesthetic norm, inadequate breast volume may lead to a negative body image, feelings of inadequacy, 
and low self-esteem. These disturbances may adversely affect a patient’s interpersonal relationships, sexual 
fulfillment, and quality of life. Since its introduction in 1962, modern breast augmentation with implants 
has become one of the most common aesthetic procedures, receiving more media attention than any other. 
It remains an increasingly popular surgical intervention today where the idealised female physique has 
morphed from the curvaceous Rubens type to one increasingly thin and androgynous, but with prominent 
breasts. The popularity of the procedure is thought to be based on the satisfaction of the patients’ results. 
Breast enlargement and reshaping with breast implants nowadays is a safe, well-accepted technique, which 
can be undertaken with ever-less frequent complications thanks to continued advances in both surgical 
technique and implant design. The purpose of the present article is to make a brief review of the history of 
breast augmentation as a surgical procedure and the evolution of breast implants.
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INTRODUCTION 
Female glandular hypomastia is a frequently 
encountered disorder that affects a significant num-
ber of women worldwide and may occur as a devel-
opmental or involutional process. Developmental 
hypomastia is often seen as primary mammary hy-
poplasia or as a sequela of thoracic hypoplasia (Po-
land syndrome) or other chest wall deformity. Invo-
lutional hypomastia may develop in the postpartum 
setting and may be exacerbated by breast-feeding 
or significant weight loss. When compared to the 
norm, inadequate breast volume may lead to a neg-
ative body image, feelings of inadequacy, and low 
self-esteem (1). These disturbances may adverse-
ly affect a patient’s interpersonal relationships, sex-
ual fulfillment, and quality of life (2). Historically, 
women have long sought breast enlargement to im-
prove physical proportions, to foster a more femi-
nine appearance, or to enhance self-image.
Following the introduction of the silicone  gel 
prosthesis in 1962 (3), breast augmentation has be-
come one of the most frequently performed opera-
tions in plastic surgery (4). It is estimated that more 
than 1% of the adult female population in the Unit-
ed States has undergone breast augmentation (5). 
In Bulgaria, similar to the majority of the European 
countries, such statistics are still missing. The wom-
en undergoing breast augmentation have been sci-
entifically scrutinised since its inception and found 
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to range from outgoing healthy individuals with a 
desire for aesthetic improvement to women with 
depression, low self-esteem, negative body image, 
and sexual inhibitions (1,2) The popularity of the 
procedure is thought to be based on the satisfaction 
of the patients' results (6). Women in general have 
enhanced self-image, increased self-assurance, im-
proved sexual functioning, and better interpersonal 
relationships after augmentation (7).
The evolution of breast augmentation
The first report of successful breast augmen-
tation appeared in 1895 in which Czerny described 
transplanting a lipoma from the trunk to the breast 
in a patient deformed by a partial mastectomy (8). 
In 1954, Longacre described a local dermal-fat flap 
for autogenous augmentation of the breast (9). 
Eventually, both adipose tissue and omentum were 
also used to augment the breast. However, the clini-
cal results of using autogenous tissue for breast aug-
mentation were often unpredictable and unaccept-
able (10).
During the 1950s and 1960s, breast augment-
ation with solid alloplastic materials was carried out 
using polyurethane, polytetrafluoroethylene (Tef-
lon), and expanded polyvinyl alcohol formaldehyde 
(Ivalon sponge). Ultimately, the use of these mate-
rials was discontinued as the majority of patients 
developed local tissue reactions, firmness, distor-
tion of the breast, and significant discomfort (11). 
Various other solid and semisolid materials have 
been injected directly into the breast parenchyma 
for augmentation, including petroleum jelly, bees-
wax, shellac, and epoxy resin (12). Uchida report-
ed the use of injectable silicone in 1961 (13). Injec-
tion of liquid silicone resulted infrequent compli-
cations, including recurrent infections, chronic in-
flammation, drainage, granuloma formation, and 
even necrosis (14,15). Because of these complica-
tions, breast augmentation by injection of free liq-
uid silicone was abandoned. 
The introduction of the silicone gel breast im-
plants in 1962 by Cronin and Gerow (3) marked the 
beginning of the modern era of breast augmenta-
tion. The silicone gel implants commercially avail-
able today are in general a refined and safer device 
than their predecessors. 
Liquid silicone (poly-dimethyl siloxane) was 
originally developed in the aeronautics to meet the 
needs of the aircraft-engineering industry during 
World War II. Because of its softness and inert na-
ture, it attracted interest from the medical sector 
and was soon evaluated as an implantable medical 
device by plastic surgical researchers (16,17). The 
Cronin and Gerow mammary implant of the 1960s, 
which was manufactured by Dow Corning (Mid-
land, Michigan, USA) (3), was composed of a vis-
cous silicone gel contained within a thick silicone 
shell in the shape of a tear drop. Seams were pres-
ent at the periphery of the device, and Dacron fix-
ation patches were placed on the posterior surfaces 
to help ensure proper position (Fig. 1). These early 
devices had such a high incidence of capsular con-
tracture that a new generation of silicone implants 
was developed by various manufacturers in the mid 
to late 1970s to produce a more natural result. These 
implants were round and characterized by a seam-
less, thin, smooth silicone shell. There were no fix-
ation patches, and the silicone gel was less viscous 
than in first-generation implants. Whereas the in-
cidence of capsular contracture may have been im-
proved somewhat, the incidence of silicone gel 
"bleed" and shell rupture was enhanced, especial-
ly from manufacturers who made very thin shells 
(18). Gel bleed is a phenomenon whereby low-mo-
lecular-weight particles of silicone gel diffuse or 
leak through the silicone elastomer shell, giving a 
sticky feel to the surface. It has been found that sili-
cone bleed could promote capsule contracture (19). 
Whether it is caused by silicone bleed or other fac-
tors, capsule contracture has been the biggest clin-
ical problem with the use of smooth-surfaced sili-
cone gel implants (4).
The third generation of smooth-surfaced sili-
cone implants, developed in the early to mid- 1980s, 
focused on improving the strength and integrity of 
the silicone shell and on minimising the silicone 
bleed phenomenon (17,18). This generation of im-
plants was characterized by two layers of high-per-
formance elastomer with a thin fluorosilicone bar-
rier coat in between. There is data to suggest that 
these improvements enhanced shell life and less-
ened capsule contracture. Third-generation sili-
cone gel implants with the application of a textured 
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surface can be considered fourth-generation devic-
es, and cohesive silicone gel-filled implants can be 
considered fifth-generation devices. Although criti-
cised for imprecision and overlap, the “generation-
al” system serves as a useful guide to implant evolu-
tion (Fig. 2) (20). The fifth-generation implants are 
discussed in more details below.
Inflatable implants
The inflatable saline-filled implant was first re-
ported by Arion in France in 1965 (21). Its invention 
and development allowed smaller incisions through 
which a noninflated device could be inserted and 
then inflated with liquid filler material. Saline im-
plants were subsequently developed by American 
manufacturers and underwent clinical evaluation in 
the early 1970s (22). The emphasis for the applica-
tion of these devices was focused on their inflatable 
nature, allowing smaller incisions, not on the char-
acter or safety of the liquid filler or an attempt to 
lessen the rates of capsular contracture.
Although it is generally accepted that the con-
tracture rate with saline implants is relatively low, 
two qualities of these devices have plagued their 
clinical use. The foremost was their   deflation rate. 
In 1968 American manufacturer Heyer-Schulte de-
veloped a saline implant with thicker and cured by 
a room-temperature vulcanized process shell (4). 
This significantly decreased the deflation rate (23). 
The second factor found to increase deflation rates 
was valve failure (24). The original Heyer Schulte 
prosthesis had a retention (leaflet) valve, which 
was subsequently replaced by a diaphragm valve. 
Saline implants currently manufactured by Men-
tor (which purchased Heyer-Schulte) and Allergan 
(formerly INAMED and McGhan Medical) have di-
aphragm valves and room-temperature vulcanised 
cured shells.
The other characteristic of saline implants that 
has been a problem relates to the saline itself, which 
may transmit visible surface wrinkles and a knuck-
le-like feel in volumetrically underfilled devices. 
When the device is overfilled, it may feel and look 
like a firm ball and transmit a peripheral "scallop-
ing" look. For these reasons, saline implants histor-
ically perform better under thicker tissue, and sur-
geons generally fill implants to the recommend-
ed volume or just beyond. It was also demonstrat-
ed that filling the implants within the recommend-
ed range or overfilling them increased device lon-
gevity and had a statistically significant effect on the 
Fig. 1. The original Cronin-Gerow silicone implant 
introduced in 1962 with teardrop shape, smooth surface, 
and Dacron patches on the posterior surface to help 
maintain the implant's position (3)
Fig. 2. Five generations of silicone gel mammary implants 
(after Independent Review Group). ACC- adverse 
capsular contracture; IMF- infra-mammary fold (20)
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implants' 10-year survival rate (25). Saline implants 
are also heavier than silicone gel implants on a vol-
umetric basis and may cause more tissue thinning 
with inferior displacement of the implant over time 
(4).
Double-lumen implants 
The original double-lumen implant was devel-
oped by Hartley as a means of countering capsular 
contracture (26). It was constructed of an inner sili-
cone gel-filled lumen surrounded by an outer saline 
inflatable shell. The concept of the device is the ini-
tial inflation of the outer saline shell to make a larg-
er pocket, with subsequent percutaneous deflation 
to leave the smaller silicone gel-filled shell within a 
larger pocket. The device became popular without 
going through these machinations as a fixed-vol-
ume, two-chamber device or as a drug delivery de-
vice, which allowed the addition of steroids or anti-
biotics to the outer saline-filled chamber.
Cox-Uphoff developed a "reverse double-
lumen" implant, which had an outer silicone gel-
filled shell surrounding an inner inflatable shell 
(27). Today, an example of double-lumen device on 
the market is the Mentor Becker prosthesis- an ex-
pander-implant used primarily for reconstruction 
(28). This device was originally developed as a sa-
line device but was subsequently converted to a re-
verse gel and saline double-lumen design to mini-
mize deflation rates. The implant functions initially 
as a tissue expander. Once the correct size has been 
obtained, the injection dome is removed, leaving 
the implant in position.
Texturized Implants 
Early attempts at augmentation with poly-
urethane sponge were not successful, but in 1970, 
Ashley reported the favorable use of a silicone gel 
implant covered with a thin layer of polyurethane 
foam (29). Although the foam was placed on the 
implant primarily to maintain its position, clinical 
use seemed to show a lessened incidence of capsular 
contracture (30). In the 1980s, it was reported that 
polyurethane covered silicone gel implants prod-
uced aesthetically satisfactory results with low cap-
sular contracture rates (31,32). The polyurethane 
surface adhered to the surrounding tissues, subse-
quently delaminated, and created a relatively non-
contractible capsule (33). Unlike smooth-surfaced 
implants that had to be mobile within their pock-
et, polyurethane-covered implants could be immo-
bile yet soft. These devices had reached a zenith of 
popularity by 1990, when questions of the safety 
of polyurethane foam break down products caused 
their withdrawal from the breast implant market 
(34).
The favorable clinical outcomes and commer-
cial success of polyurethane-covered implants led 
manufacturers to develop textured silicone surfaces 
in the hope of achieving similar results (Fig. 3) (35). 
In 1986, McGhan Medical introduced Biocell tex-
tured implants and expanders, and Mentor intro-
duced Siltex textured implants. These textured sur-
faces remain available today. In 1990, Dow Corn-
ing introduced its MSI "structured surface", but the 
company withdrew from the market two years later. 
Biocell is an aggressive open-pore textured sil-
icone surface composed of irregular pores (4,36). 
Similar to the polyurethane implants, "immobili-
ty with softness" characterizes Biocell-covered im-
plants. Prospective clinical studies have demon-
strated that Biocell textured implants have a signif-
icantly lower incidence of capsule contracture than 
do their smooth counterparts, whether they are 
filled with silicone gel or saline (37,38).
Siltex is a less aggressive textured silicone sur-
face created as a negative contact imprint off tex-
turing foam (Fig. 3) (35). Siltex does not adhere to 
the surrounding tissue and is not characterized by 
immobility with softness, as are polyurethane and 
Biocell (36). Whereas Siltex-covered implants move 
within their surrounding pocket similar to smooth-
walled implants, prospective clinical studies have 
shown a significantly lower incidence of capsule 
contracture compared with their smooth counter-
parts, whether they are filled with silicone gel  or sa-
line (39,40).
Other textured-surface devices that are current-
ly available are the polyurethane foam-covered im-
plants manufactured by Silimed in Brazil (41). 
Alternative filler implants
When safety issues with silicone gel implants 
became a concern, investigators looked for alter-
native filler substances. Among all the investigat-
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ed options, three actually came to market. Polyvi-
nylpyrrolidone is a low-molecular weight "bio-on-
cotic" gel thought to be more radiolucent than sili-
cone. It composed the fill material of the Misti Gold 
implant introduced in 1991 by Bioplasty (42). The 
polyvinylpyrrolidone implant is currently still avail-
able under the name NovaGold. In December 2000, 
the British Medical Devices Agency issued a device 
alert regarding this implant and other alternative 
filler devices, citing the opinion that studies demon-
strating the safety of these devices are lacking (43).
LipoMatrix manufactured triglyceride-filled 
implants termed "trilucent implants" in 1994. Soy-
bean oil composed the fill material, which was said 
to be radiolucent. Problems with oil bleed (44), tis-
sue irritation, and a rancid or foul smell (45) were 
reported, and the implants were withdrawn from 
the market in 1999.
Hydrogel implants are filled with an organic 
polymer, which is a mixture of polysaccharide and 
water. These implants have been manufactured in 
France by PIP and Arion. There have been reports 
of swelling of hydrogel (and polyvinylpyrrolidone) 
implants after implantation caused by osmotic gra-
dient pressure (4,43). The British Medical Devices 
Agency alert of 2000 also applied to these devices. 
Form-stable silicone gel implants 
All silicone gel implants are cross-linked to 
maintain a gel consistency, and all silicone gel has 
cohesive properties. As the cross-linking increases, 
the consistency or firmness of the liquid-feeling gel 
changes to that of a soft cheese. The enhanced cohe-
Fig. 3. (A) Polyurethane foam gains tissue adherence and delaminates from the implant. This texture fostered 
the development of textured silicone surfaces. (B) Biocell is an aggressive silicone textured surface that adheres to 
surrounding tissue by an adhesive effect. (C) Siltex is a less aggressive silicone textured surface that does not demonstrate 
any adhesive effect and does not gain tissue adherence (35)
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sive nature of these implants makes them form-sta-
ble. Thus the implant maintains its shape in all po-
sitions (shape maintenance). These implants are de-
signed in various anatomic dimensions in addition 
to round shapes and are collectively referred to as 
"cohesive silicone gel implants".  These form stable 
implants are currently popular worldwide and un-
dergoing Food and Drug Administration (FDA)-
approved clinical trials in the United States (41).
Anatomic-shaped implants 
The original Cronin and Gerow silicone gel 
implants had a tear-drop shape, as did a number 
of the early saline- and gel-filled devices. Problems 
with capsular contracture, however, led manufac-
turers to design round, smooth-surfaced low-profile 
implants, which move within their surgical pockets. 
These round smooth designs dominated the mar-
ket for nearly 20 years. Only when the phenomenon 
of immobility with softness was appreciated was the 
creation of anatomic devices clinically appropriate 
(4,39-45) The polyurethane Optimum and Replicon 
devices were early generation anatomic-shaped im-
plants popular in the 1980s (30,46). These implants 
are no longer available. 
The tissue adherence observed with tissue ex-
panders that had the Biocell surface led McGhan to 
develop anatomically shaped expanders and subse-
quently an internally stacked Style 153 gel anatom-
ic-shaped implant (4). Favorable clinical experi-
ence and advanced product design led to a matrix 
of variable height-to width ratio anatomic expand-
ers and implants, the Style 133 expanders and Style 
410 Matrix cohesive implants (Fig. 4). The latter en-
joy widespread international use in aesthetic sur-
gery (41,47). 
Mentor introduced a midheight Siltex anatom-
ic  shaped tissue expander in 1997 and other height 
options in 2003 (4). Because tissue adherence does 
not generally occur, the pocket   must be exact and 
only minimally larger than the footprint of the re-
duced height device to minimize the possibility of 
implant rotation (48). The Mentor CPG (Contour 
Profile Gel) implant is Mentor's highly cohesive 
form stable gel-filled implant. Designed to compete 
with Allergan's style 410, initially there was only a 
single size of the CPG. It now comes in a variety of 
heights and projections. The CPG gel is formulated 
to be a little softer than the 410 (Fig. 5) (49). 
Nowadays Silimed (Brazil) markets poly-
urethane-covered cohesive silicone gel implants 
in anatomic shapes (34) that enjoy international 
popularity.
Anatomic-shaped saline inflatable implants 
are manufactured by both Mentor and Inamed 
(McGhan). 
Implant regulations - safety and efficacy of 
silicone breast implants
In 1976, the US Congress passed a Medical De-
vice Amendment to the Food, Drug, and Cosmetic 
Act that gave the FDA authority over medical de-
vices. Implants on the market in the United States 
at the time or those considered “substantially equiv-
alent” to those marketed before 1976 were grand-
fathered in and allowed to remain in use until the 
FDA could formally review their safety and efficacy. 
In 1988, the FDA called for the manufacturers of sil-
icone gel-filled implants to submit their Premarket 
Approval Applications containing data adequate to 
substantiate the safety and efficacy of the devices 
they were marketing. In November 1991, the FDA 
convened an advisory panel of experts to hold pub-
lic hearings and evaluate the manufacturers' data. 
The panel concluded that more research was nec-
essary in order to establish safety and efficacy but 
recommended continued availability of plants while 
that research was performed. In January 1992, how-
ever, the FDA Commissioner went against the rec-
ommendation of the advisory panel and called for a 
voluntary moratorium on the use of silicone gel im-
plants. After further evaluation of the situation by 
the advisory panel (who thought there was a pub-
lic need for the devices), the FDA Commissioner, in 
April 1992, ruled that although silicone breast im-
plants were not necessarily unsafe, the law required 
more data to substantiate safety and efficacy than 
the manufacturers had supplied (50,51). The use of 
silicone gel implants was restricted to clinical tri-
als until the data was produced. This was interpret-
ed by the media and the public at large that silicone 
gel implants were "banned" because they were not 
safe. This effectively took silicone gel implants off 
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the market for breast augmentation in the United 
States for the next 12 years.
The moratorium on silicone breast implant 
use instituted in 1992 against the advice of the FDA 
expert panel demonstrated the contentious nature 
of the controversy surrounding silicone implants 
and associated disorders such as connective tissue 
diseases and breast cancer. Because of the scale of 
this controversy, breast implants have become the 
single most investigated medical implant device. 
Numerous large-scale epidemiologic studies have 
shown no statistically significant relevant increased 
risk of connective tissue disease in women who have 
undergone breast augmentation or reconstruction 
with silicone gel implants (49).
A literature review on the subject demonstrat-
ed numerous anecdotal and clinical reports from 
the 1980s and 1990s which hypothesize the possi-
bility of an immunologic reaction from silicone ex-
posure. More recently, however, comprehensive lit-
erature reviews such as that by Holmich et al (52), 
reinforce the large epidemiological studies and me-
ta-analyses which conclude similarly that there is no 
connection between silicone implants and defined 
connective tissue diseases or atypical, undefined 
connective tissue syndromes.
Questions about the relationship of implants 
to breast cancer have also been raised over the 
years and anecdotal reports have suggested possi-
Fig. 4. Allergan's style 410 was the first highly cohesive form-
stable gel filled implant developed. The 410 product line 
includes 12 different shapes for any given volume. These 12 
shapes make up what they call the “410 Matrix” (49) 
Fig. 5. The Mentor CPG (Contour Profile Gel) implant is 
Mentor's highly cohesive form stable gel-filled implant which 
was designed to compete with Allergan's style 410 (49)
ble links. Delayed detection and decreased surviv-
al rates in breast cancer are common concerns for 
women contemplating breast augmentation. Deap-
en methodically reviewed 21 cohort and case-con-
trol studies, representing nine different populations 
from around the world (53). The data from numer-
ous locations in the United States as well as Den-
mark, Sweden, Finland, Canada, Australia and Scot-
land consistently demonstrated no increased risk of 
cancer. In fact in many studies the relative risk was 
decreased. Furthermore, the risk of delayed detec-
tion and poorer prognosis was not borne out with 
any consistent evidence. However, it must be not-
ed that there are reports demonstrating that screen-
ing mammography is slightly impaired in patients 
with silicone or saline implants (54). The false neg-
ative rate can be higher as less tissue is visualised. 
Women with breast implants require special dis-
placement techniques (i.e. the Eklin protocol) to 
increase the efficacy of mammography and may 
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also require additional testing such as ultrasound 
or MRI to complete the workup of a questionable 
finding Mammography, however, remains the first 
line diagnostic tool of choice for these women. De-
spite the increased difficulty in screening patients 
with breast augmentation, many studies have dem-
onstrated that tumor size, disease stage, recurrence 
rates and survival remain equal in augmented pa-
tients (49).
Just as reassuring are the findings by the Insti-
tute of Medicine of the National Academy of Sci-
ences which, in 1999, was commissioned through 
congressional legislation to study the safety of sil-
icone breast implants. The Institute of Medicine's 
400-page report by an independent committee of 13 
scientists demonstrated no causal link between sil-
icone implants and systemic diseases (11). Similar-
ly, implants were not felt to be the cause of any con-
nective tissue disorder or cancer. They did, howev-
er, conclude that breast implants were responsible 
for localised problems such as capsular contracture.
Numerous independent reviews of breast im-
plant safety such as that by the Institute of Medi-
cine have been conducted. These include the World 
Health Organization, Health Canada, and the Euro-
pean Committee on Quality Assurance and Medi-
cal Devices in Plastic Surgery. They have all reached 
similar conclusions regarding the safety and efficacy 
of silicone breast implants.
CONCLUSION
Breast augmentation remains an increasing-
ly popular option today where the idealised female 
physique has morphed from the curvaceous Rubens 
type to one increasingly thin and androgynous, but 
with prominent breasts. From humble, and per-
haps somewhat disorganised, beginnings the sili-
cone gel prosthesis has now been accorded an, al-
most, clean bill of health. Whilst the dark years of 
the 1990s make for interesting reading, they at least 
catalysed a body of scientific evidence for surgeons 
and patients alike. It also demonstrates the require-
ment for science to be sufficiently robust to with-
stand highjack and subversion from a sensational-
ist, and not always patient-centred media, and for 
all parties to show patience with pioneers of novel 
techniques. The knee-jerk, anti-silicone foray into 
hydrogel and soya bean fillers was readily accept-
ed due to the pervasive ‘junk science’ furore, but 
may now be regarded as ill-considered. Certain le-
gal teams enriched themselves massively at the ex-
pense of ill-prepared organisations, such as Dow 
Corning, and one can only wonder at the outcome 
of a challenge against such a plaintiff counsel from 
a patient forced into accepting a Trilucent implant. 
Breast augmentation is a safe, well-accepted tech-
nique, which can be undertaken with ever-less fre-
quent complications thanks to continued advances 
in both technique and implant design.
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